Efficacy and safety of rituximab in myasthenia gravis: a French multicentre real‐life study

Fifteen percent of patients with myasthenia gravis (MG) are refractory to conventional treatment. Case reports and a few studies show probable benefit of rituximab in these cases. Our objective was to assess the efficacy and the safety of rituximab in patients with MG, in a multicentric real‐life study.

[1]  Versione,et al.  Common Terminology Criteria for Adverse Events , 2020, Definitions.

[2]  Mark Payne,et al.  Health and Human Services , 2020, Congress and the Nation 2013-2016, Volume XIV: Politics and Policy in the 113th and 114th Congresses.

[3]  D. Furst,et al.  Risk of Malignancies in Patients with Rheumatoid Arthritis Treated with Rituximab: Analyses of Global Postmarketing Safety Data and Long-Term Clinical Trial Data , 2019, Rheumatology and Therapy.

[4]  Yoon-Ho Hong,et al.  Repeated low-dose rituximab treatment based on the assessment of circulating B cells in patients with refractory myasthenia gravis , 2019, Therapeutic advances in neurological disorders.

[5]  Leana Doherty,et al.  Stopping oral steroid-sparing agents at initiation of rituximab in myasthenia gravis , 2019, Neuromuscular Disorders.

[6]  V. Goyal,et al.  Rituximab as induction therapy in refractory myasthenia gravis: 18 month follow-up study , 2019, Journal of Neurology.

[7]  P. Mccombe,et al.  Long-term follow-up of patients with myasthenia gravis treated with low-dose rituximab , 2018, Journal of Neurology, Neurosurgery, and Psychiatry.

[8]  R. Rojas-García,et al.  The impact of rituximab infusion protocol on the long‐term outcome in anti‐MuSK myasthenia gravis , 2018, Annals of clinical and translational neurology.

[9]  K. O’Connor,et al.  B cells in the pathophysiology of myasthenia gravis , 2018, Muscle & nerve.

[10]  G. L. Masson,et al.  Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study. , 2017, The Lancet. Neurology.

[11]  A. White,et al.  Long-term Systemic Corticosteroid Exposure: A Systematic Literature Review. , 2017, Clinical therapeutics.

[12]  G. Salles,et al.  Rituximab in B-Cell Hematologic Malignancies: A Review of 20 Years of Clinical Experience , 2017, Advances in Therapy.

[13]  M. Benatar,et al.  Rituximab as treatment for anti-MuSK myasthenia gravis , 2017, Neurology.

[14]  R. Tandan,et al.  Rituximab treatment of myasthenia gravis: A systematic review , 2017, Muscle & nerve.

[15]  F. Bolgert,et al.  Resistant myasthenia gravis and rituximab: A monocentric retrospective study of 28 patients , 2017, Neuromuscular Disorders.

[16]  M. Ticchioni,et al.  Monitoring CD27+ memory B-cells in neuromyelitis optica spectrum disorders patients treated with rituximab: Results from a bicentric study , 2017, Journal of the Neurological Sciences.

[17]  Yuebing Li,et al.  Maintenance immunosuppression in myasthenia gravis , 2016, Journal of the Neurological Sciences.

[18]  G. Shukla,et al.  Remission And relapse of myasthenia gravis on long‐term azathioprine: An ambispective study , 2016, Muscle & nerve.

[19]  M. Benatar,et al.  International consensus guidance for management of myasthenia gravis , 2016, Neurology.

[20]  M. Goldman,et al.  PML in a patient with myasthenia gravis treated with multiple immunosuppressing agents. , 2016, Neurology. Clinical practice.

[21]  Nils Erik Gilhus,et al.  Myasthenia gravis: subgroup classification and therapeutic strategies , 2015, The Lancet Neurology.

[22]  V. Damato,et al.  Efficacy and safety of rituximab for myasthenia gravis: a systematic review and meta-analysis , 2015, Journal of Neurology.

[23]  G. Wolfe,et al.  Treatment-Refractory Myasthenia Gravis , 2014, Journal of clinical neuromuscular disease.

[24]  J. Verschuuren,et al.  Long-lasting treatment effect of rituximab in MuSK myasthenia , 2012, Neurology.

[25]  K. Tyler,et al.  Rituximab-associated progressive multifocal leukoencephalopathy in rheumatoid arthritis. , 2011, Archives of neurology.

[26]  M. Conaway,et al.  Mycophenolate mofetil in AChR‐antibody‐positive myasthenia gravis: Outcomes in 102 patients , 2010, Muscle & nerve.

[27]  R. Vilallonga,et al.  Tacrolimus for Myasthenia Gravis , 2008 .

[28]  M. Pagala,et al.  Lifetime course of myasthenia gravis , 2008, Muscle & nerve.

[29]  S. Chevret,et al.  Standards of Measurements in Myasthenia Gravis , 2003, Annals of the New York Academy of Sciences.

[30]  R. Barohn,et al.  Myasthenia gravis , 2000, Neurology.

[31]  D. Furst,et al.  Low dose long-term corticosteroid therapy in rheumatoid arthritis: an analysis of serious adverse events. , 1994, The American journal of medicine.

[32]  H. Oosterhuis.  The natural course of myasthenia gravis: a long term follow up study. , 1989, Journal of neurology, neurosurgery, and psychiatry.

[33]  H. Coslett,et al.  Long‐term corticosteriod treatment of myasthenia gravis: Report of 116 Patients , 1984, Annals of neurology.